Highlights on ADHD developments from the 2022 APA annual meeting

The American Psychiatric Association Annual Meeting on June 20 provided updates on the latest research, opinions and industry practices for attention-deficit/hyperactivity disorder, the Psychiatric Times reported on June 21.

  1. Thomas Brown, PhD, of the Brown Clinic for ADHD and Related Disorders and the University of California-Riverside School of Medicine, spoke on ADHD:
  • Attention-deficit/hyperactivity disorder is not a problem of motivation.
  • People of all ages can be affected. 
  • "Every patient I've ever seen with attention-deficit/hyperactivity disorder has a few activities in which they have no difficulty utilizing their executive functions, but has a lot of difficulty with doing almost everything else. It comes down to that one phrase: if I'm interested," Dr. Brown said at the meeting. 
  • Dr. Brown's recommended tools for assessing patients for ADHD:
    • Semi-structured clinical interviews with the patient and a parent.
    • Teacher reports on the performance of students diagnosed with ADHD.
    • Standardized ADHD rating scales such as the Behavior Assessment System for Children and the Behavior Rating Inventory of Executive Function; and others.

2. Ryan Kennedy, DNP, of the Brown Clinic for ADHD and Related Disorders, spoke on pharmaceutical treatments for patients with ADHD.

  • When selecting medications for treatment, there are important factors to consider:
    • Previous medical trials
    • Growth and appetite
    • Polypharmacy
    • Metabolism
    • Comorbidity of other medications and diagnoses
    • Cost and/or insurance
    • Body chemistry
    • Best monitoring practices

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars

Top 40 articles from the past 6 months